Guanfacine in Children With Tic Disorders

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Tourette DisorderTourette Syndrome
Interventions
DRUG

placebo

Administered up to 8 weeks.

DRUG

extended-release guanfacine (Intuniv)

1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.

Trial Locations (3)

10029

Mount Sinai School of Medicine, New York

33612

University of South Florida, Tampa

06510

Yale Child Study Center, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

University of South Florida

OTHER

collaborator

Shire

INDUSTRY

collaborator

New York University

OTHER

lead

Yale University

OTHER

NCT01547000 - Guanfacine in Children With Tic Disorders | Biotech Hunter | Biotech Hunter